Leerink Partners initiated coverage on Viatris Inc. with an Outperform rating. Analysts established a price target of $20 for the global healthcare company.
Viatris recently raised its 2026 earnings guidance following a strong second quarter. The company returned to net profitability during the first half of the year.
Management continues to return capital to shareholders through dividends. Viatris also recently completed a $1.15 billion share buyback program.